← All trials
NCT06425198
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 10, 2024
- Primary completion
- Dec 23, 2024
- Completion date
- Dec 23, 2024
- First posted
- May 22, 2024
- Last posted
- Sep 26, 2024
- Enrollment
- 48
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Bristol-Myers SquibbLead sponsor
- Bristol-Myers SquibbOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.